Impact of Digoxin on Mortality in Patients with Atrial Fibrillation Stratified by Heart Failure: Findings from Gulf Survey of Atrial Fibrillation Events in the Middle East

Ibrahim Al-Zakwani, P. Panduranga, M. Zubaid, K. Sulaiman, W. A. Rashed, A. A. Alsheikh-Ali, W. Almahmeed, A. Shehab, A. Al Qudaimi, N. Asaad, H. Amin

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: The use of digoxin in patients having atrial fibrillation (AF) with or without heart failure (HF) is not without controversy. The aim of this study was to examine the impact of digoxin therapy on mortality stratified by HF. Methods: Gulf Survey of Atrial Fibrillation Events was a prospective, multinational, observational registry of consecutive patients with AF recruited from the emergency department of 23 hospitals in 6 countries in the Middle East. Patients were recruited between October 2009 and June 2010 and followed up for 1 year after enrollment. Analyses were performed using univariate and multivariate statistical techniques. Results: The study included a total of 1962 patients with AF, with an overall mean age of 56 ± 16 years, and 52% (n = 1026) were males. At hospital discharge, digoxin was prescribed in 36% (n = 709) of the patients, whereas HF was present in 27% (n = 528) of the cohort. A total of 225 (12.1%) patients died during the 12-month follow-up period after discharge (5.3% [n = 104] were lost to follow-up). Patients with HF were consistently associated with higher mortality at 1 month (5.1% vs 2.1%; P

Original languageEnglish
Pages (from-to)273-279
Number of pages7
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Volume21
Issue number3
DOIs
Publication statusPublished - 2015

Fingerprint

Middle East
Digoxin
Atrial Fibrillation
Heart Failure
Mortality
Lost to Follow-Up
Surveys and Questionnaires
Registries
Hospital Emergency Service

Keywords

  • atrial fibrillation
  • digoxin
  • heart failure
  • middle east
  • mortality

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Impact of Digoxin on Mortality in Patients with Atrial Fibrillation Stratified by Heart Failure : Findings from Gulf Survey of Atrial Fibrillation Events in the Middle East. / Al-Zakwani, Ibrahim; Panduranga, P.; Zubaid, M.; Sulaiman, K.; Rashed, W. A.; Alsheikh-Ali, A. A.; Almahmeed, W.; Shehab, A.; Al Qudaimi, A.; Asaad, N.; Amin, H.

In: Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 21, No. 3, 2015, p. 273-279.

Research output: Contribution to journalArticle

Al-Zakwani, Ibrahim ; Panduranga, P. ; Zubaid, M. ; Sulaiman, K. ; Rashed, W. A. ; Alsheikh-Ali, A. A. ; Almahmeed, W. ; Shehab, A. ; Al Qudaimi, A. ; Asaad, N. ; Amin, H. / Impact of Digoxin on Mortality in Patients with Atrial Fibrillation Stratified by Heart Failure : Findings from Gulf Survey of Atrial Fibrillation Events in the Middle East. In: Journal of Cardiovascular Pharmacology and Therapeutics. 2015 ; Vol. 21, No. 3. pp. 273-279.
@article{7fba86eef35c42fcb7ad4232cc5c2a41,
title = "Impact of Digoxin on Mortality in Patients with Atrial Fibrillation Stratified by Heart Failure: Findings from Gulf Survey of Atrial Fibrillation Events in the Middle East",
abstract = "Objective: The use of digoxin in patients having atrial fibrillation (AF) with or without heart failure (HF) is not without controversy. The aim of this study was to examine the impact of digoxin therapy on mortality stratified by HF. Methods: Gulf Survey of Atrial Fibrillation Events was a prospective, multinational, observational registry of consecutive patients with AF recruited from the emergency department of 23 hospitals in 6 countries in the Middle East. Patients were recruited between October 2009 and June 2010 and followed up for 1 year after enrollment. Analyses were performed using univariate and multivariate statistical techniques. Results: The study included a total of 1962 patients with AF, with an overall mean age of 56 ± 16 years, and 52{\%} (n = 1026) were males. At hospital discharge, digoxin was prescribed in 36{\%} (n = 709) of the patients, whereas HF was present in 27{\%} (n = 528) of the cohort. A total of 225 (12.1{\%}) patients died during the 12-month follow-up period after discharge (5.3{\%} [n = 104] were lost to follow-up). Patients with HF were consistently associated with higher mortality at 1 month (5.1{\%} vs 2.1{\%}; P",
keywords = "atrial fibrillation, digoxin, heart failure, middle east, mortality",
author = "Ibrahim Al-Zakwani and P. Panduranga and M. Zubaid and K. Sulaiman and Rashed, {W. A.} and Alsheikh-Ali, {A. A.} and W. Almahmeed and A. Shehab and {Al Qudaimi}, A. and N. Asaad and H. Amin",
year = "2015",
doi = "10.1177/1074248415603505",
language = "English",
volume = "21",
pages = "273--279",
journal = "Journal of Cardiovascular Pharmacology and Therapeutics",
issn = "1074-2484",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Impact of Digoxin on Mortality in Patients with Atrial Fibrillation Stratified by Heart Failure

T2 - Findings from Gulf Survey of Atrial Fibrillation Events in the Middle East

AU - Al-Zakwani, Ibrahim

AU - Panduranga, P.

AU - Zubaid, M.

AU - Sulaiman, K.

AU - Rashed, W. A.

AU - Alsheikh-Ali, A. A.

AU - Almahmeed, W.

AU - Shehab, A.

AU - Al Qudaimi, A.

AU - Asaad, N.

AU - Amin, H.

PY - 2015

Y1 - 2015

N2 - Objective: The use of digoxin in patients having atrial fibrillation (AF) with or without heart failure (HF) is not without controversy. The aim of this study was to examine the impact of digoxin therapy on mortality stratified by HF. Methods: Gulf Survey of Atrial Fibrillation Events was a prospective, multinational, observational registry of consecutive patients with AF recruited from the emergency department of 23 hospitals in 6 countries in the Middle East. Patients were recruited between October 2009 and June 2010 and followed up for 1 year after enrollment. Analyses were performed using univariate and multivariate statistical techniques. Results: The study included a total of 1962 patients with AF, with an overall mean age of 56 ± 16 years, and 52% (n = 1026) were males. At hospital discharge, digoxin was prescribed in 36% (n = 709) of the patients, whereas HF was present in 27% (n = 528) of the cohort. A total of 225 (12.1%) patients died during the 12-month follow-up period after discharge (5.3% [n = 104] were lost to follow-up). Patients with HF were consistently associated with higher mortality at 1 month (5.1% vs 2.1%; P

AB - Objective: The use of digoxin in patients having atrial fibrillation (AF) with or without heart failure (HF) is not without controversy. The aim of this study was to examine the impact of digoxin therapy on mortality stratified by HF. Methods: Gulf Survey of Atrial Fibrillation Events was a prospective, multinational, observational registry of consecutive patients with AF recruited from the emergency department of 23 hospitals in 6 countries in the Middle East. Patients were recruited between October 2009 and June 2010 and followed up for 1 year after enrollment. Analyses were performed using univariate and multivariate statistical techniques. Results: The study included a total of 1962 patients with AF, with an overall mean age of 56 ± 16 years, and 52% (n = 1026) were males. At hospital discharge, digoxin was prescribed in 36% (n = 709) of the patients, whereas HF was present in 27% (n = 528) of the cohort. A total of 225 (12.1%) patients died during the 12-month follow-up period after discharge (5.3% [n = 104] were lost to follow-up). Patients with HF were consistently associated with higher mortality at 1 month (5.1% vs 2.1%; P

KW - atrial fibrillation

KW - digoxin

KW - heart failure

KW - middle east

KW - mortality

UR - http://www.scopus.com/inward/record.url?scp=84963665525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963665525&partnerID=8YFLogxK

U2 - 10.1177/1074248415603505

DO - 10.1177/1074248415603505

M3 - Article

C2 - 26341119

AN - SCOPUS:84963665525

VL - 21

SP - 273

EP - 279

JO - Journal of Cardiovascular Pharmacology and Therapeutics

JF - Journal of Cardiovascular Pharmacology and Therapeutics

SN - 1074-2484

IS - 3

ER -